Chemotherapy-induced cardiotoxicity in children

Neha Bansal, Shahnawaz Amdani, Emma R. Lipshultz, Steven E Lipshultz

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: With advances in clinical oncology, the burden of morbidity and mortality for cancer survivors due to the cardiac side effects of the chemotherapy is steadily increasing. Treatment-related cardiac damage is progressive and often irreversible. Primary prevention of cardiotoxicity during treatment is possible with strategies like limiting the cumulative anthracycline dose, the use of anthracycline structural analogs, and especially cardioprotective agents. Areas covered: This review covers the various cardiotoxic chemotherapeutic agents, the pathophysiology of cardiotoxicity due to anthracyclines, and the clinical and subclinical presentations and progression of childhood anthracycline cardiotoxicity. We also discuss preventive measures and strategies, especially the cardioprotectant agent dexrazoxane where there is strong evidence-based support for its use with anthracycline chemotherapy. However, there is a paucity of evidence-based recommendations for diagnosing and treating cancer therapy-induced cardiovascular complications. Finally, we discuss the potential of cardio-oncology. Expert opinion: There is no ‘safe’ anthracycline dose if the goal is normal long-term cardiovascular status but higher lifetime cumulative doses of anthracyclines, higher dose rates, female sex, longer follow-up, younger age at anthracycline treatment, pre-existing cardiovascular disease, and cardiac irradiation are associated with more severe cardiotoxicity. With deeper understanding of the mechanisms of the adverse cardiac effects and identification of driver mutations causing these effects, personalized cancer therapy to limit cardiotoxic effects can be achieved, such as with the cardioprotectant dexrazoxane.

Original languageEnglish (US)
Pages (from-to)817-832
Number of pages16
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume13
Issue number8
DOIs
StatePublished - Aug 3 2017
Externally publishedYes

Fingerprint

Chemotherapy
Anthracyclines
Drug Therapy
Dexrazoxane
Oncology
Cardiotoxins
Cardiotonic Agents
Therapeutics
Neoplasms
Preexisting Condition Coverage
Medical Oncology
Cardiotoxicity
Expert Testimony
Primary Prevention
Survivors
Cardiovascular Diseases
Irradiation
Morbidity
Mutation
Mortality

Keywords

  • anthracycline
  • cardio-oncology
  • cardiotoxicity
  • Childhood cancer
  • survivorship

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Chemotherapy-induced cardiotoxicity in children. / Bansal, Neha; Amdani, Shahnawaz; Lipshultz, Emma R.; Lipshultz, Steven E.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 13, No. 8, 03.08.2017, p. 817-832.

Research output: Contribution to journalReview article

Bansal, Neha ; Amdani, Shahnawaz ; Lipshultz, Emma R. ; Lipshultz, Steven E. / Chemotherapy-induced cardiotoxicity in children. In: Expert Opinion on Drug Metabolism and Toxicology. 2017 ; Vol. 13, No. 8. pp. 817-832.
@article{ba6648d39ac94a2b9e1c9b5d3627fac5,
title = "Chemotherapy-induced cardiotoxicity in children",
abstract = "Introduction: With advances in clinical oncology, the burden of morbidity and mortality for cancer survivors due to the cardiac side effects of the chemotherapy is steadily increasing. Treatment-related cardiac damage is progressive and often irreversible. Primary prevention of cardiotoxicity during treatment is possible with strategies like limiting the cumulative anthracycline dose, the use of anthracycline structural analogs, and especially cardioprotective agents. Areas covered: This review covers the various cardiotoxic chemotherapeutic agents, the pathophysiology of cardiotoxicity due to anthracyclines, and the clinical and subclinical presentations and progression of childhood anthracycline cardiotoxicity. We also discuss preventive measures and strategies, especially the cardioprotectant agent dexrazoxane where there is strong evidence-based support for its use with anthracycline chemotherapy. However, there is a paucity of evidence-based recommendations for diagnosing and treating cancer therapy-induced cardiovascular complications. Finally, we discuss the potential of cardio-oncology. Expert opinion: There is no ‘safe’ anthracycline dose if the goal is normal long-term cardiovascular status but higher lifetime cumulative doses of anthracyclines, higher dose rates, female sex, longer follow-up, younger age at anthracycline treatment, pre-existing cardiovascular disease, and cardiac irradiation are associated with more severe cardiotoxicity. With deeper understanding of the mechanisms of the adverse cardiac effects and identification of driver mutations causing these effects, personalized cancer therapy to limit cardiotoxic effects can be achieved, such as with the cardioprotectant dexrazoxane.",
keywords = "anthracycline, cardio-oncology, cardiotoxicity, Childhood cancer, survivorship",
author = "Neha Bansal and Shahnawaz Amdani and Lipshultz, {Emma R.} and Lipshultz, {Steven E}",
year = "2017",
month = "8",
day = "3",
doi = "10.1080/17425255.2017.1351547",
language = "English (US)",
volume = "13",
pages = "817--832",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Chemotherapy-induced cardiotoxicity in children

AU - Bansal, Neha

AU - Amdani, Shahnawaz

AU - Lipshultz, Emma R.

AU - Lipshultz, Steven E

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Introduction: With advances in clinical oncology, the burden of morbidity and mortality for cancer survivors due to the cardiac side effects of the chemotherapy is steadily increasing. Treatment-related cardiac damage is progressive and often irreversible. Primary prevention of cardiotoxicity during treatment is possible with strategies like limiting the cumulative anthracycline dose, the use of anthracycline structural analogs, and especially cardioprotective agents. Areas covered: This review covers the various cardiotoxic chemotherapeutic agents, the pathophysiology of cardiotoxicity due to anthracyclines, and the clinical and subclinical presentations and progression of childhood anthracycline cardiotoxicity. We also discuss preventive measures and strategies, especially the cardioprotectant agent dexrazoxane where there is strong evidence-based support for its use with anthracycline chemotherapy. However, there is a paucity of evidence-based recommendations for diagnosing and treating cancer therapy-induced cardiovascular complications. Finally, we discuss the potential of cardio-oncology. Expert opinion: There is no ‘safe’ anthracycline dose if the goal is normal long-term cardiovascular status but higher lifetime cumulative doses of anthracyclines, higher dose rates, female sex, longer follow-up, younger age at anthracycline treatment, pre-existing cardiovascular disease, and cardiac irradiation are associated with more severe cardiotoxicity. With deeper understanding of the mechanisms of the adverse cardiac effects and identification of driver mutations causing these effects, personalized cancer therapy to limit cardiotoxic effects can be achieved, such as with the cardioprotectant dexrazoxane.

AB - Introduction: With advances in clinical oncology, the burden of morbidity and mortality for cancer survivors due to the cardiac side effects of the chemotherapy is steadily increasing. Treatment-related cardiac damage is progressive and often irreversible. Primary prevention of cardiotoxicity during treatment is possible with strategies like limiting the cumulative anthracycline dose, the use of anthracycline structural analogs, and especially cardioprotective agents. Areas covered: This review covers the various cardiotoxic chemotherapeutic agents, the pathophysiology of cardiotoxicity due to anthracyclines, and the clinical and subclinical presentations and progression of childhood anthracycline cardiotoxicity. We also discuss preventive measures and strategies, especially the cardioprotectant agent dexrazoxane where there is strong evidence-based support for its use with anthracycline chemotherapy. However, there is a paucity of evidence-based recommendations for diagnosing and treating cancer therapy-induced cardiovascular complications. Finally, we discuss the potential of cardio-oncology. Expert opinion: There is no ‘safe’ anthracycline dose if the goal is normal long-term cardiovascular status but higher lifetime cumulative doses of anthracyclines, higher dose rates, female sex, longer follow-up, younger age at anthracycline treatment, pre-existing cardiovascular disease, and cardiac irradiation are associated with more severe cardiotoxicity. With deeper understanding of the mechanisms of the adverse cardiac effects and identification of driver mutations causing these effects, personalized cancer therapy to limit cardiotoxic effects can be achieved, such as with the cardioprotectant dexrazoxane.

KW - anthracycline

KW - cardio-oncology

KW - cardiotoxicity

KW - Childhood cancer

KW - survivorship

UR - http://www.scopus.com/inward/record.url?scp=85026243586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026243586&partnerID=8YFLogxK

U2 - 10.1080/17425255.2017.1351547

DO - 10.1080/17425255.2017.1351547

M3 - Review article

C2 - 28679288

AN - SCOPUS:85026243586

VL - 13

SP - 817

EP - 832

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 8

ER -